RxDoctor Payments Data

Brian Geary, MD

Urology · Macon, GANPI 1275737223

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by Astellas Pharma US Inc at 34.7% of the total. Reporting peaked in 2019 at $11,888 and has fallen 88.7% since, to $1,346 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,899in general payments, 2019–2025

Across 494 payments — averaging $54.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$9K
  • Medtronic$4K
  • Neotract Inc.$3K
  • Urovant Sciences Inc$2K
  • Cook Medical LLC$1K
  • Boston Scientific$1K
  • plus $6K from 46 others

What the payments were for

  • Speaking & faculty fees$8,55532%
  • Travel & lodging$5,45920%
  • Food & beverage$12,79248%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,899 in reported general payments places this provider in the 90th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$173,696
Medicare patients
484
Services billed
22,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron238$171,197
GemtesaVibegron123$104,540
Solifenacin Succinate123$6,400
Trospium Chloride ErTrospium Chloride25$3,545
Finasteride223$2,610
Oxybutynin Chloride181$1,930
Tamsulosin Hcl138$1,543
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst85$998
Trospium Chloride13$794
Oxybutynin Chloride ErOxybutynin Chloride43$725
Ciprofloxacin Hcl211$516
Hyoscyamine Sulfate20$394
Doxycycline Monohydrate27$264
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$244
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$9,346$171,197238 claims
Sumitomo Pharma America, Inc.Gemtesa$157$104,540123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 369 urology providers in Georgia.

Other urology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →